S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Laser breakthrough could send stock soaring 2,467% (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Laser breakthrough could send stock soaring 2,467% (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Laser breakthrough could send stock soaring 2,467% (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Is This The Collapse of Icahn Enterprises ?
Laser breakthrough could send stock soaring 2,467% (Ad)
20 Best Healthcare Dividend Stocks to Invest in
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Laser breakthrough could send stock soaring 2,467% (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
Laser breakthrough could send stock soaring 2,467% (Ad)
What Does the Airbnb Guidance Drop Say About Travel Demand?
What is the Penalty for Excess Contributions to an IRA?
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Forecast, Price & News

$1.71
+0.08 (+4.91%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.59
▼
$1.77
50-Day Range
$1.32
▼
$2.17
52-Week Range
$0.66
▼
$5.78
Volume
1.22 million shs
Average Volume
1.82 million shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Summit Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Summit Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$412.29 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.06 out of 5 stars

Medical Sector

1949th out of 1,980 stocks

Pharmaceutical Preparations Industry

959th out of 978 stocks

See Top Rated MarketRank™ Stocks Here

SMMT stock logo

About Summit Therapeutics (NASDAQ:SMMT) Stock

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMMT Stock News Headlines

June 2, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Trading 4.5% Higher
June 1, 2023 | finance.yahoo.com
Ivonescimab Updated Data to be Featured at ASCO 2023
June 2, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 26, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Trading Down 5.9%
May 26, 2023 | americanbankingnews.com
Traders Buy High Volume of Summit Therapeutics Call Options (NASDAQ:SMMT)
May 22, 2023 | finance.yahoo.com
11 Stocks with Heavy Insider Buying in 2023
May 18, 2023 | finance.yahoo.com
After buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b
May 18, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.83
June 2, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 16, 2023 | finance.yahoo.com
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript
May 16, 2023 | finance.yahoo.com
Why Shares of Summit Therapeutics Slumped on Tuesday
May 13, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Downgraded by StockNews.com to "Sell"
May 12, 2023 | finance.yahoo.com
Q1 2023 Summit Therapeutics Inc Earnings Call
May 11, 2023 | seekingalpha.com
Summit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call Transcript
May 11, 2023 | finance.yahoo.com
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
May 11, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.94
April 13, 2023 | seekingalpha.com
Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere
April 12, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%
April 8, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $1.57
March 23, 2023 | americanbankingnews.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.6%
March 21, 2023 | businesswire.com
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
March 21, 2023 | reuters.com
SMMT.O
March 13, 2023 | insidermonkey.com
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2022 Earnings Call Transcript
March 9, 2023 | finance.yahoo.com
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
March 3, 2023 | finance.yahoo.com
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
February 1, 2023 | finance.yahoo.com
Bullish insiders bet US$97m on Summit Therapeutics Inc. (NASDAQ:SMMT)
January 30, 2023 | finance.yahoo.com
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
See More Headlines

SMMT Price History

SMMT Company Calendar

Last Earnings
3/09/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
CUSIP
N/A
CIK
1599298
Web
www.summitplc.com
Phone
650-460-8308
Fax
44-12-3544-3999
Employees
105
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,780,000.00
Net Margins
-1,012.41%
Pretax Margin
-17,289.16%
Return on Equity
-70.92%
Return on Assets
-26.95%

Debt

Debt-to-Equity Ratio
0.75
Current Ratio
14.22
Quick Ratio
14.22

Sales & Book Value

Annual Sales
$700,000.00
Price / Sales
1,704.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
9.00

Miscellaneous

Outstanding Shares
697,680,000
Free Float
113,723,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
-1.02

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 79)
    CEO & Exec. Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 53)
    M.B.A., MBA, Co-CEO, Pres & Director
    Comp: $651.45k
  • Dr. Urte Gayko Ph.D. (Age 52)
    Head of Regulatory Affairs, Quality Assurance & Safety and Director
    Comp: $7.76k
  • Prof. Dame Kay Davies DBE (Age 72)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Mr. Ankur Dhingra (Age 47)
    Chief Financial Officer
  • Ms. Michelle Avery
    Director of Investor Relations
  • Dr. Elaine Carla Stracker J.D. (Age 62)
    Ph.D., Head of Compliance? & Gen. Counsel
  • Mr. Campbell Hair
    Head of HR?
  • Dr. Anne Heatherington
    Head of Clinical Devel. and Quantitative Sciences
  • Ms. Divya Chari (Age 55)
    Head of Global Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SMMT Stock - Frequently Asked Questions

How have SMMT shares performed in 2023?

Summit Therapeutics' stock was trading at $4.25 on January 1st, 2023. Since then, SMMT shares have decreased by 59.8% and is now trading at $1.71.
View the best growth stocks for 2023 here.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SMMT earnings forecast.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Thursday, March, 9th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $1.13 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 70.92% and a negative net margin of 1,012.41%.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (0.90%), BlackRock Inc. (0.26%), Geode Capital Management LLC (0.16%), Steward Partners Investment Advisory LLC (0.09%), Two Sigma Investments LP (0.07%) and HRT Financial LP (0.06%). Insiders that own company stock include Ankur Dhingra, David Jonathan Powell, Mahkam Zanganeh, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $1.71.

How much money does Summit Therapeutics make?

Summit Therapeutics (NASDAQ:SMMT) has a market capitalization of $1.19 billion and generates $700,000.00 in revenue each year. The company earns $-78,780,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Summit Therapeutics have?

The company employs 105 workers across the globe.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The official website for the company is www.summitplc.com. The company can be reached via phone at 650-460-8308, via email at investors@summitplc.com, or via fax at 44-12-3544-3999.

This page (NASDAQ:SMMT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -